Effects of Allulose vs Aspartame Consumption on Postprandial GLP-1 Profiles and Metabolic Health: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Allulose vs Aspartame: Do They Behave Differently in the Body?

A randomized, double-blind, crossover trial in healthy adults compared how allulose and aspartame affect postprandial GLP-1 — one of the body's key metabolic hormones. The protocol, published in JMIR Research Protocols, tests a question at the center of sweetener science: are all low-calorie sweeteners metabolically equivalent?

Why GLP-1 Is the Focus

GLP-1 (glucagon-like peptide-1) is a master metabolic hormone. It triggers insulin release when glucose rises, suppresses glucagon, slows stomach emptying, and signals fullness to the brain. It is also the target of blockbuster weight-loss drugs like semaglutide (Ozempic/Wegovy).

If a sweetener naturally nudges GLP-1, it could support appetite and glucose regulation through diet alone.

Allulose and Aspartame Are Not the Same Kind of Molecule

	Allulose	Aspartame
Type	Rare sugar (low-calorie)	Artificial high-intensity sweetener
Calories	<0.4 kcal/g	~4 kcal/g, used in trace amounts
In the body	Partially absorbed, ~90% excreted	Metabolized to amino acids
Sweetness vs sucrose	~70%	~200x
Known GLP-1 effect	Stimulates gut L-cells	Generally inert

The distinction matters. Allulose has shown GLP-1-stimulating activity in animal and some human work. Aspartame, like most artificial sweeteners, does not meaningfully stimulate GLP-1.

How the Trial Was Designed

Randomized, crossover, double-blind, placebo-controlled — the standard gold design for dietary studies. Each participant received allulose, aspartame, and a control under identical conditions, with postprandial blood drawn at multiple time points to build GLP-1 response curves.

The crossover design lets each person serve as their own control, which gives the study good statistical power with a modest sample size.

What the Findings Imply

The working hypothesis: allulose would produce a different postprandial GLP-1 profile than aspartame, reflecting allulose's interaction with intestinal L-cells.

• If allulose raises GLP-1, it supports positioning as a "functional sweetener" with appetite-regulating potential
• If aspartame does not, it sharpens the line between low-calorie sugars and artificial sweeteners

For manufacturers, the value is human evidence that separates allulose from artificial sweeteners on metabolic grounds.

Implications for Formulators

Application	Relevance
Appetite-regulation products	A possible allulose satiety angle
Diabetic-friendly foods	A hormonal profile distinct from artificial sweeteners
Clean label	"Naturally occurring rare sugar" vs "artificial"
Claim substantiation	Human trial data beats animal data

A realistic caveat: allulose's GLP-1 effect is modest compared with pharmacologic GLP-1 receptor agonists. No "weight loss" or "treatment" claim is appropriate. The honest framing is "supports natural appetite and glucose regulation," backed by human evidence.

Frequently Asked Questions

Q: Is allulose better than aspartame? They fill different formulation roles. This trial examines hormonal (GLP-1) differences, not which is "better." Allulose offers a rare-sugar profile with potential GLP-1 activity; aspartame is a high-intensity sweetener used at trace levels.

Q: Does allulose spike insulin? No. Allulose has a negligible glycemic response and has been shown to attenuate postprandial glucose and insulin across multiple studies.

Q: Can I substitute allulose for aspartame 1:1? No. Allulose is ~70% as sweet as sucrose; aspartame is ~200x sweeter. Formulations must be adjusted accordingly.

Wrap-Up

This human crossover trial directly compares the GLP-1 response to allulose versus aspartame, testing whether a low-calorie rare sugar behaves differently from an artificial sweetener. The results will shape both sweetener science and how allulose is positioned in products targeting metabolic health.

Read the full paper: JMIR Research Protocols | DOI: 10.2196/81857